antifungal resistance – Page 4

New Strategies to Combat Human Fungal Infections

mycolabadmin

Fungal infections are becoming a major global health threat, causing millions of deaths annually. This research collection presents new and improved ways to treat these infections, including natural compounds like chitosan, beneficial bacteria, new drug combinations, and tests to better understand which treatments work best. The papers showcase innovative approaches beyond traditional antifungal medications to help combat resistant infections.

Antifungal susceptibility testing of Microsporum canis isolated from the skin of dermatologically healthy cats

mycolabadmin

Researchers found that about 5% of healthy cats in Chile carry a fungal infection called Microsporum canis that can spread to humans. The concerning discovery is that all strains tested were resistant to fluconazole, a commonly used antifungal medication. The study shows that indoor cats are at higher risk of carrying this fungus and suggests that screening healthy cats could help prevent transmission to people who have close contact with them.

Occurrence of Pathogenic and Allergenic Molds in the Outdoor and Indoor Environment of a Major Hospital and Molecular Epidemiology of Aspergillus fumigatus in Kuwait

mycolabadmin

Researchers studied molds found in and around a major hospital in Kuwait over 17 months, collecting over 6,000 mold samples. They discovered various mold species, including some that can cause serious infections in hospital patients. Importantly, they found drug-resistant Aspergillus fumigatus strains both outdoors and inside the hospital, suggesting the environment may be a source of infection for vulnerable patients. The findings highlight the need for better monitoring and control of molds in hospital settings.

Emerging antifungal resistance in Trichophyton mentagrophytes: insights from susceptibility profiling and genetic mutation analysis

mycolabadmin

This study examined how common skin fungal infections caused by Trichophyton species are becoming resistant to standard antifungal treatments. Researchers tested 131 fungal isolates from China and analyzed their resistance genes to understand why some strains no longer respond to terbinafine and other antifungal drugs. They found that certain genetic mutations, particularly in the SQLE gene, make these fungi resistant to treatment and that different species have different resistance patterns. These findings help doctors better choose treatments and guide the development of new antifungal medications.

Invasive Trichoderma longibrachiatum breakthrough infection in a hematology patient

mycolabadmin

A 61-year-old woman with blood cancer developed a severe and unusual double fungal infection caused by two mold species while being treated for a known fungal infection. Despite receiving multiple antifungal medications, her condition worsened and she ultimately died from multiple organ failure. The case is important because it demonstrates how Trichoderma fungi are becoming dangerous pathogens in very sick, immunocompromised patients, and a new drug called olorofim showed promising activity against this infection in laboratory tests.

Drug repurposing to fight resistant fungal species: Recent developments as novel therapeutic strategies

mycolabadmin

Fungal infections are becoming increasingly difficult to treat due to growing drug resistance, affecting millions of people worldwide each year. This research collection explores creative solutions by repurposing existing medications and developing new combination therapies that work better together against resistant fungal species. Studies show promising results combining common antibiotics like minocycline with antifungal drugs, and natural compounds from traditional medicine show potential for treating hard-to-treat infections like Candida and Aspergillus.

A prospective, multicenter study of invasive fungal disease caused by molds in children and adults in Chile

mycolabadmin

Researchers studied serious fungal infections caused by molds in Chilean hospitals and found that aspergillus was the most common culprit, affecting both children and adults. Many patients with these infections were also suffering from COVID-19, showing how serious respiratory viruses can increase the risk of fungal complications. Good news: the study found no resistance to common antifungal medications in Chile yet, though overall survival rates remain concerning at around 60% at three months.

Metabolic Patterns of Fluconazole Resistant and Susceptible Candida auris Clade V and I

mycolabadmin

Researchers used advanced chemical analysis to identify different compounds produced by a dangerous fungus called Candida auris that can cause serious infections. They compared fungal strains that were resistant to the antifungal drug fluconazole with those that were susceptible, finding that resistant strains produced different metabolites (chemical compounds) than susceptible ones. These findings could help doctors develop better treatments by identifying what makes this fungus resistant to current medications.

Emergence of resistant dermatophytosis caused by Trichophyton indotineae: First case series in Thailand

mycolabadmin

Researchers in Thailand have identified five patients with a difficult-to-treat fungal skin infection caused by Trichophyton indotineae, a type of dermatophyte that resists the commonly used antifungal drug terbinafine. This is the first time this resistant fungus has been detected in Thailand. The team developed a simple, inexpensive test using urease to help identify these resistant infections more easily. Patients responded well to the antifungal drug itraconazole after other treatments failed.

Spread of Antifungal-Resistant Trichophyton indotineae, United Kingdom, 2017–2024

mycolabadmin

A fungal infection called Trichophyton indotineae, which originated in Asia, is rapidly spreading throughout the United Kingdom and becoming resistant to common antifungal treatments. The infection typically starts in the groin area and can spread to other parts of the body, and many cases fail to respond to standard antifungal drugs like terbinafine. Researchers tracked 157 cases over seven years and found the fungus now accounts for over a third of all dermatophyte infections sent to the UK reference laboratory. Doctors and laboratory professionals are being urged to recognize this emerging threat and consider better diagnostic and treatment strategies.

Research Topic: antifungal resistance